Latest Breaking News On - Restated prospectus supplement - Page 1 : comparemela.com
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NervGen Pharma Corp : NervGen Pharma Announces Results of Annual General Meeting of Shareholders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NervGen Pharma Corp.: NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Vancouver, British Columbia (Newsfile Corp. - April 14, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee ( HREC ) in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma inhibitor. We are pleased that the HREC found our modified development program to be acceptable and the receipt of ethics approval marks a significant milestone in the advancement of NVG-291 into the clinic, stated Paul Brennan, NervGen s President & CEO. We intend to build on this momentum and look forward to evaluating the therapeutic potential of NVG-291 in patients upon successful
NervGen Pharma Corp.: NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia (Newsfile Corp. - April 8, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.
Paul Brennan, NervGen s President & CEO, stated, We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were able to resubmit our Investigational New Drug Application for NVG-291 early in 2021 and we look forward to starting our Phase 1 trial in Australia this quarter. We continue to generate encouraging preclinical data to support our programs to bring life-changing hope to many people suffering from nerve damage as a result of injury or neurodegenerative diseases. Pending successful completion of our Phase 1 stud
vimarsana © 2020. All Rights Reserved.